Jiangsu

Jiangsu Hengrui Pharmaceuticals, commonly known as Hengrui Medicine, is a leading global pharmaceutical company headquartered in Lianyungang, China. It is recognized as one of the largest and most innovative pharmaceutical entities in China, focusing on the research, development, and commercialization of high-quality drugs across oncology, metabolic diseases, autoimmune disorders, and pain management. The company has successfully transitioned from a generic manufacturer to an innovation-driven powerhouse, with a robust pipeline of novel small molecules and biologics, including several internally developed PD-1 inhibitors and antibody-drug conjugates. Hengrui maintains a significant global footprint with R&D centers in China, the United States, and Europe, and frequently engages in high-profile out-licensing deals with international biotech and pharma partners.